Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
168 hedge funds and large institutions have $1.14B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 55 increasing their positions, 44 reducing their positions, and 25 closing their positions.
61% more capital invested
Capital invested by funds: $706M → $1.14B (+$432M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
44% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 25
25% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 44
6% more funds holding
Funds holding: 159 → 168 (+9)
30% less call options, than puts
Call options by funds: $22.6M | Put options by funds: $32.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$36.7M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$34.7M |
| 3 |
FAM
Fred Alger Management
New York
|
+$30.9M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$16.3M |
| 5 |
Morgan Stanley
New York
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$45.5M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$12.6M |
| 3 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$10.1M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$7.74M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$7.41M |
RETA Hedge Fund Activity: Q4 2022 in Review
168 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q4 2022, worth a combined $1.14B — up 61% from $706M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new RETA positions and 25 closed out — a net gain of 11 holders — while 55 added to existing stakes and 44 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $36.7M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $45.5M sold.
- 168 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q4 2022, up from 159 in Q3 2022.
- Funds reported $1.14B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q4 2022, up 61% quarter-over-quarter.
- 36 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q4 2022 and 25 closed out, a net change of +11 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q4 2022 was Adage Capital Partners, an estimated $36.7M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q4 2022 was Point72 Asset Management, an estimated $45.5M sold.
Based on aggregated 13F filings for Q4 2022.